Kornimate/medical-research-clean huggingface dataset:
the diagnostic value of nitrogen element (n) in esophagus cancer

Conditions: Esophageal Cancer

Summary: the purpose of this study is to determine the diagnostic value of various nitrogen isotopes(n) in oral gas for esophagus cancer (esca) .

less effective diagnostic markers for esca can be used in present. nitrogen elements include a variety of nitrogen isotopes with various mass. stable nitrogen isotope ratios 15 nitrogen/14 nitrogen (15 n/14 n) are of particular advantage to understand the metabolic state of cancer cells, since most biochemical reactions involve transfer of nitrogen. cancerous cells can recycle metabolic ammonium for their growth . the recycling of this ammonium with a low nitrogen isotope ratio (15 n/14 n) may cause cancer tissue to have lower 15 n/14 n than surrounding healthy tissue, and it could diagnose malignancy as well as an avenue for investigation of cancer metabolism. however, the relationship and diagnostic value between nitrogen excretion from oral gas and esca remains unclear. the purpose of this study is to analyze the diagnostic value of various mass nitrogen isotope excreting for oral gas for esca.

Eligibility criteria:
inclusion criteria: * esophageal cancer patient * reflux esophagitis patient * 18-80 years old exclusion criteria: * esophageal or gastric surgery * history of previous upper abdominal surgery * history of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection * history of other malignant disease within past five years * history of previous neoadjuvant chemotherapy or radiotherapy * history of unstable angina or myocardial infarction within past six months * history of cerebrovascular accident within past six months * requirement of simultaneous surgery for other disease * emergency surgery due to complication (bleeding, obstruction or perforation) caused by cancer * pregnant women or breastfeeding * unwillingness or inability to consent for the study * severe mental disorder * unstable vital signs coagulation dysfunction (inr\>1.5) * low peripheral blood platelet or using anti coagulation drugs * long-term chinese medicine treatment of unknown drug nature

Keywords: esophageal cancer nitrogen isotope diagnosis
rtms in spastic hemiplegic cerebral palsy children

Conditions: Cerebral Palsy

Summary: the aim of the work is to study the role of repetitive transcranial magnetic stimulation (rtms) in spastic hemiplegic cerebral palsy in a sample of egyptian children.

prior to start of rtms therapy, gross motor function classification system (gmfcs) will be employed on the participants to classify gross motor function. also, modified ashworth scale (mas) scoring will be employed on the participants to access spasticity on selected muscles namely, hamstring, soleus, gastrocnemius and adductor of lower limb; and bicep, supinator and wrist extensor of upper limb. rtms frequency of 10 hz will be delivered to each of the participants in the study group for 15 minutes per session. each session will be administered once daily for 2 days a week for 4 weeks. 1500 pulses (50 pulses per train with total 30 trains having inter- train delay of 25 seconds) per session will be provided with the coil placed on the contralateral primary motor cortex (m1) which is known to produce modulatory effect on muscle tightness of the limbs (rajak et al. 2017). rtms frequency of 10 hz was kept constant based on previous studies with 5 hz and 10 hz (anttila et al. 2008) (rossi 2009). each session will be followed by physical therapy (pt) according to physiotherapy protocol. after completion of therapeutic programs (after 4 weeks), the participants will be asked to undergo post assessment of gross motor function classification system (gmfcs), and modified ashworth scale (mas) scoring on exactly the same muscles as recorded previously. both pt and rtms sessions will be administered by trained professionals who was kept blinded to the research protocols used in the study.

Eligibility criteria:
inclusion criteria: 1. willingness to participate. 2. age group between 4 and 18 years. 3. they are able to walk with limitation or holding on according to gross motor function classification system (gmfcs) (level ii, iii, iv). 4. all patients have mild to moderate spasticity according to modified ashworth scale (grade 1, 1+,2). exclusion criteria: * all children with: 1. perceptual defects (iq\<70). 2. use of botulinum toxin in the past 4 months. 3. convulsions. 4. other peripheral or central nervous system dysfunction. 5. fixed deformities in lower limbs. 6. clinically suspected active inflammatory or pathologic changes in lower limb joints during the previous 6 months. 7. clinically suspected active medical problems, such as pneumonia, meningitis, encephalitis, upper gastrointestinal bleeding, or urinary tract infection. 8. metabolic disorders, such as inborn error of metabolism, electrolyte, and endocrine disorders. 9. metallic implants.

Keywords: cerebral palsy
a multicenter, double-blind, phase iii, adjuvant-controlled study of the effect of 10 units of hiv-1 immunogen (remune) compared to incomplete freund's adjuvant (ifa) alone every 12 weeks on aids-free survival in subjects with hiv infection and cd4 t-lymphocytes between 300 and 549 cells/microl rega

Conditions: HIV Infections

Summary: to determine the effect of hiv-1 immunogen (remune) on aids-free survival, defined as the time prior to development of an aids-defining condition or death.

patients receive 10 units of hiv-1 immunogen in ifa or ifa alone every 12 weeks, then are followed for 104-148 weeks.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * antiretrovirals if on a stable dose for at least the past 3 months. patients must have: * hiv-1 infection with cd4 count 300-549 cells/mm3. * no aids-defining condition. * been on a stable dose of antiretroviral for the past 3 months, if taking antiretrovirals. note: * ks is permitted if not requiring systemic therapy. prior medication: allowed: * prior antiretrovirals. exclusion criteria concurrent medication: excluded: * systemic chemotherapy for ks. * treatment for malignancy other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. patients with the following prior conditions are excluded: * history of any illness that would interfere with study. * acute infection requiring prescription therapy within the past month, other than genital herpes and oral or vaginal candidiasis. prior medication: excluded: * prior hiv-1 immunogen. unwilling to use effective safe sex practices. active substance abuse.

Keywords: vaccines, synthetic viral vaccines hiv-1 aids-related complex aids vaccines salk hiv immunogen
feasibility and acceptability of an web-based physical activity program, for those diagnosed with lung cancer.

Conditions: Lung Cancer; Survivorship

Summary: lung cancer is a life changing disease which can cause negative effects on an individual's ability to perform daily tasks and their quality of life (qol). lung cancer is the third most common cancer in the uk and is estimated affects approximately 33,000 individuals per year. the most common side effects from lung cancer and treatments are breathlessness, fatigue, nausea, diarrhoea, and depression. those living beyond cancer often suffer from extreme feelings of isolation and have increased chance of cardiovascular disease and diabetes. physical activity is a vital component of the prevention and management of cancer. being active can improve one's physical health (ability to carry out tasks of daily living and breathlessness) and emotional wellbeing (feelings of depression and isolation). electronic platforms (websites and mobile applications) are increasingly popular within developing nations, particularly with products that aim to increase and keep track of physical activity. though, literature suggests older adults prefer websites opposed to mobile applications. online delivery of physical activity could be highly beneficial for patients living with and beyond cancer, reducing the location-based inequality of those who can not attend face-to-face programmes, allowing individuals to carry out a session whenever they can, in the comfort of their own home. exploring how those living with and beyond lung cancer use a website and investigating the feasibility and acceptability on an online platform which aims to provide tailored physical activity programs will provide fundamental data and possible supporting data for a randomised controlled trail (rct).


Eligibility criteria:
inclusion criteria: * be 18 years of age or older. * have had a lung cancer diagnosis. * be able to speak and read in english. * willing and able to provide informed consent. * have internet connectivity. * access to a laptop, computer, or smart device to access the web-based platform. exclusion criteria: * psychological or linguistic inability to provide informed consent. * physical or psychological impairments which prevent or inhibit participation in physical activity. examples include: * uncontrolled atrial fibrillation * abdominal aortic aneurysm (aaa) * recent heart attack (less than one year) * recent stroke (less than one year) * psychiatric disorder * those who lack capacity under the mental capacity act 2005 (mca).

Keywords: physical activity exercise digtial technology
68ga-p3 pet/ct imaging in prostate

Conditions: Neoplasms

Summary: prostate-specific membrane antigen (psma) is a type ii transmembrane glycoprotein that consists of 750 amino acids. it is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making psma a highly specific and significant imaging target for malignancies. \[68ga\]p3, a novel molecular probe of pet imaging agent that targets psma, can be used in the diagnosis and research of a wide variety of psma high-expression malignanciesr.

prostate-specific membrane antigen (psma) is a type ii transmembrane glycoprotein that consists of 750 amino acids. it is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making psma a highly specific and significant imaging target for malignancies.\[68ga\]p3, a novel molecular probe of pet imaging agent that targets psma, can be used in the diagnosis and research of a wide variety of psma high-expression malignanciesr.

Eligibility criteria:
inclusion criteria: patients with confirmed or suspected cancer; signed written informed consent exclusion criteria:

Keywords: [68ga]p3 psma pet/ct neoplasms
a study to assess the efficacy, safety and pharmacokinetics of eyu688 in patients with dengue fever

Conditions: Dengue

Summary: the purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of eyu688 compared with placebo in patients with dengue fever.

this is a randomized, participant- and investigator- blinded, placebo-controlled study to investigate the efficacy and safety of eyu688 administered orally in patients with dengue fever. due to the different pk sampling schedules applied, the study consists of two cohorts run in parallel (intensive pk \[cohort 1\] and sparse pk sampling \[cohort 2\]).

Eligibility criteria:
inclusion criteria: * male or female, 18 - 60 years old (inclusive). * history or presence of fever (≥ 38°c). at least one of the following criteria indicating dengue infection: * nausea or vomiting. * presence of rash, aches or pains including headache, muscle or joint pain. * onset of fever ≤ 48 hours prior to treatment start. * positive test on dengue fever. exclusion criteria: * participants with any of abnormalities of clinical laboratory parameters. * usage of any anticoagulant drugs. * current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug. * pregnant or nursing (lactating) women. * clinical signs and symptoms for severe dengue according to dengue guideline (who 2009) at screening. * participants with any of the following abnormalities of clinical laboratory parameters at screening: * hemoglobin \<12.0 g/dl in males; \<11.0 g/dl in females * hematocrit \>52 % in males; \>46 % in females * absolute neutrophil count \<1500/μl * platelet count \<80,000/mm3 * creatinine \>165 μmol/l in males; \>130 μmol/l in females * serum creatine kinase \> 600 u/l * alt, ast levels more than 1.5x upper limit of normal (uln) * total bilirubin \>24 μmol/l * usage of ppis (proton pump inhibitor) which could affect absorption of eyu688 due to stomach ph value increase up to 48 hours prior to screening. * women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug. * history or long-qt syndrome, or clinically significant ecg abnormalities, or any of the following ecg abnormalities at screening: * qtcf \> 450 msec (males) * qtcf \> 460 msec (females) other protocol-defined inclusion/exclusion criteria may apply.

Keywords: dengue eyu688
deep marginal acquisition with thermacut bur vs. functional crown lengthening in deep carious lesions

Conditions: Deep Caries

Summary: this clinical trial is conducted to compare between deep marginal acquistion by the means of thermacut bur vs. functional crown lengthening in exposing deep subgingival interproximal cervical lesions

deep subgingival margins pose a great difficulty during restorative work with composite restorations. exposing cavity margins is paramount in order to attain proper isolation, matrix adaptation and composite placement. several methods have been proposed to overcome the problem of exposing deep margins; functional crown lengthening is considered the gold standard of care regarding exposure of deep margins. however, functional crown lengthening can pose many problems including the risk of root exposure, furcation involvement and compromising crown root ratio, besides risk of thread exposure if it is done beside implant, removal of bone from adjacent teeth and from buccal and lingual walls in order to create smooth bone architecture, and the complications of surgery such as post-operative pain, inflammation and edema and the risk of excessive bleeding. deep marginal acquisition and deep marginal extension (dma \& dme) are considered as a viable option in treating deep subgingival extended margins. several methods regarding deep marginal acquisition have been proposed including the use of diode laser and electrosurgery, there is another protocol for exposing the gingival seat by the use of thermacut bur. the rationale behind conducting this research is to propose an easy and predictable way to expose deep subgingival margins, without the need to perform surgical intervention. the technique is done by clinicians with good outcomes, but never been tested or validated, this study is performed to verify whether this test should be validated or not.

Eligibility criteria:
inclusion criteria: - subject not less than 18 years of age 1. males or females 2. community-dwelling 3. have at least one deep subgingival interproximal carious lesion. 4. can comply to oral hygiene measures or with good oral hygiene 5. have sufficient cognitive ability to 5- understand consent procedures. exclusion criteria: 1. patients less than 18 years old. 2. disabilities: 3. systemic diseases or severe medically compromised. (cardiovascular disorder, diabetes, hypertensive, epileptic). 4. lack of compliance. 5. gingival hyperplasia, blood disorder. 6. cognitive impairment. 7. attachment loss signs of periodontal disease.
long term follow-up study of human immunodeficiency virus type 1 (hiv-1) positive patients who have received oz1 gene therapy as part of a clinical trial

Conditions: HIV-1

Summary: the purpose of this observational study is long term follow-up of the human immunodeficiency virus -1 (hiv-1) infected patients who have received a gene therapy product (anti-hiv-1 ribozyme \[oz1\]) as part of an earlier phase 2 trial. patients are seen twice yearly until 5 years from initial infusion of study drug has elapsed and then yearly until withdrawal or study completion. the study will monitor for and record any ill effects from the gene therapy product to provide long term safety information.

during an earlier phase 2 base trial (study # nct00074997), hiv-1 infected patients received a gene therapy product (anti-hiv-1 ribozyme \[oz1\]). gene therapy is an investigational treatment where genes are inserted into an individual's cells and tissues to treat a disease. the gene therapy oz1 is thought to have anti-hiv-1 actions. this is an observational study to provide long term follow-up of those hiv-1 infected patients who received the gene therapy product (anti-hiv-1 ribozyme \[oz1\]) as part of the earlier study. patients are seen twice yearly until 5 years from initial infusion of study drug has elapsed and then yearly until withdrawal or study completion. the study will monitor for and record any ill effects from the gene therapy product to provide long term safety information. observational study - no investigational drug administered.

Eligibility criteria:
inclusion criteria: * all patients who were enrolled (between 18 and 45 years of age) in the base study "oth/oz1-int-1" (nct00074997) will be invited to participate in this long term follow-up study * patients must have received the final cell product infusion in base study "oth/oz1-int-1" * have signed informed consent form exclusion criteria: * all patients who were enrolled in the oth/oz1-int-1 study and received the final cell product will be invited to participate in this long term follow-up study. after unblinding of the oth/oz1-int-1 study, any patients in the placebo arm will be withdrawn from this protocol

Keywords: gene therapy anti-hiv-1 ribozyme oz1 hiv-1 infections
phase iii study of botulax® to treat post stroke upper limb spasticity

Conditions: Stroke; Spasticity

Summary: the purpose of this study is to evaluate the safety and efficacy of botulax® compared to botox® reducing upper limb muscle tone in post stroke patients.


Eligibility criteria:
inclusion criteria: 1. male and female patients, over 20 years of age 2. patients with a history of stroke more than 6weeks prior to enrollment 3. focal spasticity of wrist flexor measured with modified ashworth scale (mas) of 2 or greater at wrist and 1 or greater at least one of elbow flexor and finger flexor 4. a minimum grade of 2 or greater on the disability assessment scale(das) for targeted one functional disability item (i.e., hygiene, dressing, pain, or limb position) 5. patients who signed informed consent form, clearly understand the intent of the study and are able to comply with instructions to complete the entire study exclusion criteria: 1. patients with diagnosed neuromuscular disorders such as lamber-eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis 2. patients with profound atrophy of the muscle in the target limb 3. patients with fixed joint/muscle contracture\* in the target limb * defined as inability to passively move the joints 4. patients with history within 6 months or planned to have treatment with phenol or alcohol injection(chemodenervation) in the target limb 5. patients with history within 6 months or planned to have treatment with tendon lengthening in the target limb 6. patients who have concurrent treatment with an intrathecal baclofen 7. patients who had received botulinum toxin injection within the past 3 months(for cosmetic purpose is allowed) 8. patients with concurrent or planned to take muscle relaxants and/or benzodiazepine medication (allowed to participate if patient has consistently taken these medication from a month before screening visit and no changes in therapy are planned during the study) 9. patients with concurrent or planned to have physical, occupational, or splinting therapy (allowed to participate if these therapies were consistently taken from a month before screening visit and no treatment changes are planned during the study 10. patients with a known allergy or sensitivity to the study medication or its components (clostridium botulinum toxin type a, albumin, sodium chloride, etc.) 11. patients who have participated in other clinical trials 1 month prior to this study 12. male and female who are not willing to take any appropriate means of contraception or to have ascetic life at least 2 months after treatment 13. patients who are not eligible for this study at the discretion of the investigator

Keywords: stroke spasticity
population pharmacokinetics of prolonged infusion meropenem in cystic fibrosis (cf) children

Conditions: Cystic Fibrosis; Pneumonia; Pseudomonas Aeruginosa Infection

Summary: this study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation. safety and practicality of administering meropenem as a 3 hour infusion will be measured.

this study will be conducted at 7 pediatric hospitals in the united states (columbia university medical center, new york, new york; university of north carolina, chapel hill, north carolina; st. christopher's hospital for children, philadelphia, pennsylvania, connecticut children's medical center, hartford, connecticut, riley hospital for children, indianapolis, indiana, nationwide hospital for children, columbus, ohio, and children's medical center, dallas, texas). cystic fibrosis children (age 6-17 years) admitted to one of these enrolling sites with an acute exacerbation of his or her pulmonary infection who require antibiotic therapy with meropenem will be eligible. meropenem will be administered as a 3 hour prolonged infusion and blood concentrations will be measured to determine the population pharmacokinetics in 30 patients, the safety of prolonged infusion meropenem, and the practicality as measured be treatment burden using a questionaire. the population pharmacokinetic model developed will be utilized to determine the optimal dose of meropenem to administer to children with cystic fibrosis, and define an exposure response relationship for the drug in this population.

Eligibility criteria:
inclusion criteria: * cystic fibrosis * hospitalized with acute pulmonary exacerbation * caused by pseudomonas aeruginosa or other bacteria against which meropenem would be an appropriate antibiotic treatment exclusion criteria: * known allergy to meropenem * require less than 3 days of meropenem in the hospital * require another systemic beta-lactam antibiotic to treat a concomitant pathogen * known fungal or viral infection * females in their 2nd or 3rd trimester of pregnancy * moderate to severe renal dysfunction, as defined by a creatinine clearance less than 50 ml/min/1.73m2 (by use of schwartz method) * history of solid organ transplantation within previous 6 months * active or recent (within 30 days) participation in another antibiotic clinical trial

Keywords: cystic fibrosis acute pulmonary exacerbations pseudomonas aeruginosa